• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by UL Solutions Inc.

    11/8/24 1:08:21 PM ET
    $ULS
    Precision Instruments
    Health Care
    Get the next $ULS alert in real time by email
    SC 13G 1 sc13g.htm SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    SCHEDULE 13G
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    UL Solutions Inc.
    (Name of Issuer)
    Class A common stock, par value $0.001 per share
    (Title of Class of Securities)
    903731107
    (CUSIP Number)
    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐
    Rule 13d-1(b)

    ☐
    Rule 13d-1(c)

    ☑
    Rule 13d-1(d)
    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosure provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of the section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    1
    NAME OF REPORTING PERSON
     
    ULSE Inc.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)         ☐
    (b)         ☐
    3
    SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    138,130,000(1)
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    138,130,000(1)
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    138,130,000(1)
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    69.06%(2)
    12
    TYPE OF REPORTING PERSON
    CO

    (1)
    Reflects 138,130,000 shares of Class B common stock held directly by ULSE Inc., which are convertible at any time at the option of the holder into Class A common stock on a one-for-one basis. ULSE Inc. is managed by a board of directors consisting of Philip S. Khoury, James M. Shannon and Joel R. Wittenberg, none of whom, acting individually, has voting control or investment discretion with respect to the securities owned. Underwriters Laboratories Inc., a Delaware charitable nonstock corporation, is the sole member of ULSE Inc. Underwriters Laboratories Inc. is managed by a board of trustees consisting of James P. Dollive, Philip S. Khoury, Richard P. Owen, Darryll Pines, Mark Schmid, James M. Shannon, Elisabeth Tørstad and George A. Williams, none of whom, acting individually, has voting control or investment discretion with respect to the securities owned by ULSE Inc.

    (2)
    The percentage of Class A common stock is based on 61,876,949 shares of Class A common stock outstanding as of September 5, 2024, the date of effectiveness of the Issuer’s Registration Statement on Form S-1 (Registration 333-281902) filed with the Securities and Exchange Commission (the “SEC”) on September 3, 2024, plus 138,130,000 shares of Class A common stock issuable upon the conversion of Class B common stock.



    1
    NAME OF REPORTING PERSON
     
    Underwriters Laboratories Inc.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)         ☐
    (b)         ☐
    3
    SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    138,130,000(1)
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    138,130,000(1)
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    138,130,000(1)
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    69.06%(2)
    12
    TYPE OF REPORTING PERSON
    CO

    (1)
    Reflects 138,130,000 shares of Class B common stock held directly by ULSE Inc., which are convertible at any time at the option of the holder into Class A common stock on a one-for-one basis. ULSE Inc. is managed by a board of directors consisting of Philip S. Khoury, James M. Shannon and Joel R. Wittenberg, none of whom, acting individually, has voting control or investment discretion with respect to the securities owned. Underwriters Laboratories Inc., a Delaware charitable nonstock corporation, is the sole member of ULSE Inc. Underwriters Laboratories Inc. is managed by a board of trustees consisting of James P. Dollive, Philip S. Khoury, Richard P. Owen, Darryll Pines, Mark Schmid, James M. Shannon, Elisabeth Tørstad and George A. Williams, none of whom, acting individually, has voting control or investment discretion with respect to the securities owned by ULSE Inc.

    (2)
    The percentage of Class A common stock is based on 61,876,949 shares of Class A common stock outstanding as of September 5, 2024, the date of effectiveness of the Issuer’s Registration Statement on Form S-1 (Registration 333-281902) filed with the Securities and Exchange Commission (the “SEC”) on September 3, 2024, plus 138,130,000 shares of Class A common stock issuable upon the conversion of Class B common stock.



    Item 1(a)
    Name of Issuer
    The name of the issuer is UL Solutions Inc. (the “Issuer”).
    Item 1(b)
    Address of Issuer’s Principal Executive Offices
    The Issuer’s principal executive offices are located at: 333 Pfingsten Rd., Northbrook, Illinois 60062.
    Item 2(a)
    Name of Person Filing
    This statement is filed by the following (each hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons”):

    (i)
    ULSE Inc., a Delaware nonprofit nonstock corporation, which directly holds Class B common stock; and

    (ii)
    Underwriters Laboratories Inc., a Delaware charitable nonstock corporation, which is the sole member of ULSE Inc.
    The Joint Filing Agreement among the Reporting Persons to file this Schedule 13G jointly in accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is filed as Exhibit A herein.
    Item 2(b)
    Address of Principal Business Office or, if None, Residence
    The address of the business office of the Reporting Person is: 1603 Orrington Ave, Suite 2000, Evanston, Illinois 60201.
    Item 2(c)
    Citizenship
    See Item 4 of each of the cover pages.
    Item 2(d)
    Title of Class of Securities
    Class A common stock, par value $0.001 per share.
    Item 2(e)
    CUSIP No.
    903731107
    Item 3.
    If This Statement is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
    Not Applicable.
    Item 4.
    Ownership

    (a)
    Amount Beneficially Owned:  See Item 9 of each of the cover pages.

    (b)
    Percent of Class:  See Item 11 of each of the cover pages.

    (c)
    Number of Shares as to which such person has:



    (i)
    Sole power to vote or direct the vote:  See Item 5 of each of the cover pages.

    (ii)
    Shared power to vote or direct the vote:  See Item 6 of each of the cover pages.

    (iii)
    Sole power to dispose or direct the disposition:  See Item 7 of each of the cover pages.

    (iv)
    Shared power to dispose or direct the disposition:  See Item 8 of each of the cover pages.
    Item 5.
    Ownership of Five Percent or Less of a Class
    Not applicable.
    Item 6.
    Ownership of More Than Five Percent on Behalf of Another Person
    Not applicable.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group
    Not applicable.
    Item 9.
    Notice of Dissolution of Group
    Not applicable.
    Item 10.
    Certification
    Not applicable.



    SIGNATURES
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 8, 2024

     
    ULSE Inc.
       
     
    By:  
    /s/ Ron H. Blaustein
       
    Name: Ron H. Blaustein
       
    Title: Senior Vice President and Chief Financial Officer
       
     
    Underwriters Laboratories Inc.
       
     
    By:
    /s/ D. Michael Murray
       
    Name: D. Michael Murray
       
    Title: Vice President, Corporate and Legal Affairs

    Get the next $ULS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ULS

    DatePrice TargetRatingAnalyst
    5/14/2025$71.00Buy → Neutral
    Citigroup
    10/7/2024$60.00Buy
    Citigroup
    7/12/2024$41.00 → $46.00Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $ULS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • UL Solutions to Attend Upcoming Investor Conferences

      UL Solutions Inc. (NYSE:ULS), a global leader in applied safety science, today announced that senior management of the company will participate in the following investor conferences: William Blair 45th Annual Growth Stock Conference, June 3 Stifel 2025 Boston Cross Sector 1x1 Conference, June 4 and Baird 2025 Global Consumer, Technology & Services Conference, June 5. The company's presentation at the William Blair 45th Annual Growth Stock Conference, at 3:00 p.m. EDT (2:00 p.m. CDT) on June 3, will be broadcast live. The webcast can be accessed through the UL Solutions Investor Relations website at ir.ul.com. A replay of the webcast will be available on the website for 30 days a

      5/29/25 4:45:00 PM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Announces Quarterly Dividend

      UL Solutions Inc. (NYSE:ULS), a global leader in applied safety science, today announced that its board of directors has declared a quarterly dividend of $0.13 per share. The dividend will be paid on June 9 to shareholders of record as of the close of business on May 30. About UL Solutions A global leader in applied safety science, UL Solutions Inc. (NYSE:ULS) transforms safety, security and sustainability challenges into opportunities for customers in more than 110 countries. UL Solutions delivers testing, inspection and certification services, together with software products and advisory offerings, that support our customers' product innovation and business growth. The UL Mark serves a

      5/20/25 6:32:00 PM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Launches Advanced Battery Testing Center in Europe

      The UL Solutions Europe Advanced Battery Laboratory in Aachen, Germany, provides testing, simulation and certification services addressing automotive and stationary battery research, safety and performance. UL Solutions Inc. (NYSE:ULS) today announced the opening of its Europe Advanced Battery Testing Laboratory in Aachen, Germany, which will test batteries used in electric vehicles (EVs) and large-scale energy storage systems, significantly expanding the company's battery technology testing capabilities and its European footprint. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513936962/en/Guests celebrate the opening of the

      5/15/25 8:00:00 AM ET
      $ULS
      Precision Instruments
      Health Care

    $ULS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UL Solutions Inc. downgraded by Citigroup with a new price target

      Citigroup downgraded UL Solutions Inc. from Buy to Neutral and set a new price target of $71.00

      5/14/25 8:58:56 AM ET
      $ULS
      Precision Instruments
      Health Care
    • Citigroup resumed coverage on UL Solutions Inc. with a new price target

      Citigroup resumed coverage of UL Solutions Inc. with a rating of Buy and set a new price target of $60.00

      10/7/24 8:45:25 AM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Inc. downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded UL Solutions Inc. from Outperform to Neutral and set a new price target of $46.00 from $41.00 previously

      7/12/24 7:43:51 AM ET
      $ULS
      Precision Instruments
      Health Care

    $ULS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Thaman Michael H

      4 - UL Solutions Inc. (0001901440) (Issuer)

      6/11/25 5:15:54 PM ET
      $ULS
      Precision Instruments
      Health Care
    • SEC Form 4 filed by Director Dollive James P

      4 - UL Solutions Inc. (0001901440) (Issuer)

      6/11/25 5:15:51 PM ET
      $ULS
      Precision Instruments
      Health Care
    • SEC Form 4 filed by Director Susman Sally

      4 - UL Solutions Inc. (0001901440) (Issuer)

      6/11/25 5:15:47 PM ET
      $ULS
      Precision Instruments
      Health Care

    $ULS
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by UL Solutions Inc.

      SCHEDULE 13G/A - UL Solutions Inc. (0001901440) (Subject)

      6/6/25 12:06:11 PM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - UL Solutions Inc. (0001901440) (Filer)

      5/22/25 4:36:38 PM ET
      $ULS
      Precision Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by UL Solutions Inc.

      SCHEDULE 13G/A - UL Solutions Inc. (0001901440) (Subject)

      5/12/25 10:43:30 AM ET
      $ULS
      Precision Instruments
      Health Care

    $ULS
    Leadership Updates

    Live Leadership Updates

    See more

    $ULS
    Financials

    Live finance-specific insights

    See more

    $ULS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • UL Solutions Inc. Names New Chief Legal Officer

      UL Solutions Inc. (NYSE:ULS), a global leader in applied safety science, today announced it appointed Scott D'Angelo as executive vice president and chief legal officer, effective April 21, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250311928632/en/UL Solutions names Scott D'Angelo as executive vice president and chief legal officer (Photo: Business Wire) D'Angelo's appointment fills a vacant role and he joins the company's executive leadership team, reporting to President and CEO Jennifer Scanlon. D'Angelo will oversee the legal, brand integrity, ethics and compliance functions. He most recently served as vice presiden

      3/11/25 9:15:00 AM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Names Chief Business Operations and Innovation Officer

      Alex Dadakis to join UL Solutions leadership team in newly created role UL Solutions Inc. (NYSE:ULS), a global leader in applied safety science, today announced it appointed Alex Dadakis as Executive Vice President, Chief Business Operations and Innovation Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205299962/en/UL Solutions announced the appointment of Alex Dadakis as Executive Vice President, Chief Business Operations and Innovation Officer, effective Jan. 27, 2025. (Photo: Business Wire) Dadakis, who most recently served as Senior Vice President, Global Head of Strategy and Corporate Development at Germany-ba

      12/5/24 4:15:00 PM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Acquires Germany-Based Battery Testing and Simulation Company BatterieIngenieure

      Deal deepens UL Solutions' global expertise in battery performance testing and expands our global EV battery testing footprint. UL Solutions Inc. (NYSE:ULS), a global leader in applied safety science, today announced our acquisition of BatterieIngenieure GmbH, a battery testing company based in Aachen, Germany, with expertise in specialized performance testing of cell, small modules and battery systems used in electric vehicles and other applications. The acquisition augments UL Solutions' global battery testing footprint with a laboratory in Europe. BatterieIngenieure provides comprehensive testing, simulation and failure analysis of battery technologies, with distinctive expertise in

      5/22/24 8:30:00 AM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Announces Quarterly Dividend

      UL Solutions Inc. (NYSE:ULS), a global leader in applied safety science, today announced that its board of directors has declared a quarterly dividend of $0.13 per share. The dividend will be paid on June 9 to shareholders of record as of the close of business on May 30. About UL Solutions A global leader in applied safety science, UL Solutions Inc. (NYSE:ULS) transforms safety, security and sustainability challenges into opportunities for customers in more than 110 countries. UL Solutions delivers testing, inspection and certification services, together with software products and advisory offerings, that support our customers' product innovation and business growth. The UL Mark serves a

      5/20/25 6:32:00 PM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Inc. Reports Strong First Quarter 2025 Results

      First Quarter 2025 (Comparisons to First Quarter 2024 unless otherwise noted)1 Strong revenue growth of 5.2% to $705 million, including 7.6% organic growth Net income of $71 million increased 18.3%, Net income margin of 10.1%, expanded 110 basis points Diluted earnings per share of $0.33 increased 17.9%, Adjusted Diluted Earnings Per Share of $0.37 increased 32.1% Adjusted EBITDA of $161 million increased 22.9%, Adjusted EBITDA margin of 22.8% expanded 320 basis points UL Solutions Inc. (NYSE:ULS), a global safety science leader in independent third-party testing, inspection and certification services and related software and advisory offerings, today reported results for the firs

      5/6/25 7:00:00 AM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Inc. Sets Date for First Quarter 2025 Results

      UL Solutions Inc. (NYSE:ULS), a global leader in applied safety science, today announced it will release financial results for the first quarter 2025 before the market opens on Tuesday, May 6. Management will host a webcast and conference call that same day at 8:30 a.m. EDT (7:30 a.m. CDT) to review results. Webcast and Conference Call The conference call will be broadcast live over the Internet. Additionally, a slide presentation will accompany the conference call. To listen to the call and view the slides, please visit the Investors section of UL Solutions' website at www.ul.com. For those who are unable to listen to the live broadcast, an audio replay of the conference call will be ava

      4/22/25 7:00:00 AM ET
      $ULS
      Precision Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by UL Solutions Inc.

      SC 13G/A - UL Solutions Inc. (0001901440) (Subject)

      11/13/24 12:26:41 PM ET
      $ULS
      Precision Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by UL Solutions Inc.

      SC 13G/A - UL Solutions Inc. (0001901440) (Subject)

      11/12/24 5:49:12 PM ET
      $ULS
      Precision Instruments
      Health Care
    • SEC Form SC 13G filed by UL Solutions Inc.

      SC 13G - UL Solutions Inc. (0001901440) (Subject)

      11/12/24 10:34:15 AM ET
      $ULS
      Precision Instruments
      Health Care